Your Messages Inbox
Your Article Summary
See Latest ArticlesRandomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)
Leukemia and Lymphoma, 09/18/09
Zenhausern R et al. – Daily administration of 2–chlorodeoxyadenosine (Cladribine, CDA) is a standard treatment for hairy cell leukemia, but may cause severe neutropenia and neutropenic fever. This trial compared toxicity and efficacy of weekly versus daily CDA administration. The findings indicate that there are no apparent advantages in toxicity and efficacy by giving CDA weekly rather than daily.
Related Articles
T-box-expressed-in-T-cells (T-bet) expression by the tumor cells of hairy cell leukemia correlates with interferon-gamma production
Leukemia and Lymphoma, 10/30/09
Relevance Score: 83%
Hairy cell leukemia presenting as multiple discrete hepatic lesions
World Journal of Gastroenterology, 10/06/09
Relevance Score: 83%
Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia
International Journal of Hematology, 10/23/09
Relevance Score: 82%
Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms
Modern Pathology, 10/07/09
Relevance Score: 82%
Management of hematological malignancies during pregnancy
American Journal of Hematology, 10/27/09
Relevance Score: 80%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09
Article Search
Sponsor